B+
Bull case
0%
Probability
Target price
$220.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
BIIB
BiogenCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
0%
Probability
Target price
$203.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$170.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-29
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+56.4
Score
AI commentary
Post-earnings tone is mixed and should remain a monitoring view. Recent headlines emphasized both the Q1 beat and the lowered 2026 earnings outlook, while trusted coverage described an initially positive share reaction. That supports a tentative improvement in tone, but analyst revision coverage is unavailable at this T+1 stage and the 2026 guidance reset, Apellis financing, and legacy-product pressure keep forward evidence limited.
RankAlpha Sentiment Codex - 2026-04-29
Open full AI memoEvidence flagged
memo remains a monitoring view with limited forward evidence and should not be standard-conviction
Impact
tentative
Confidence
-
AI events
2026-05-06catalystQ1 beat offsets part of the guidance cut in near-term tape digestionMedium impact
Biogen reported Q1 2026 revenue of $2.478 billion and non-GAAP EPS of $3.57, while updating 2026 non-GAAP EPS guidance to $14.25-$15.25 from $15.25-$16.25 because of roughly $1.00 of acquired IPR&D charges tied to business-development activity; trusted coverage described an initially positive share reaction despite the reduced earnings outlook. [#8-K-2026-04-29]
2026-05-24eventLEQEMBI subcutaneous autoinjector FDA decision on May 24, 2026Medium impact
The 10-Q says the FDA accepted the supplemental BLA for LEQEMBI IQLIK with a May 24, 2026 PDUFA date, creating a dated regulatory catalyst for Alzheimer’s franchise convenience and uptake. [#10-Q-2026-04-29]
2027-04-29catalystApellis close and nephrology buildout could reshape the 2026-2027 growth mixMedium impact
Biogen expects the Apellis acquisition to close in Q2 2026, fund it with about $3.6 billion of cash/marketable securities plus about $2.0 billion of bank loans, and later provide updated 2026 guidance inclusive of Apellis; the company also acquired Greater China rights to felzartamab, reinforcing the nephrology strategy. [#8-K-2026-04-29] [#10-Q-2026-04-29]
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-29 • Updated nightlySource: Internal modelMethodology